- Your Challenges
- Offerings
- News & Events
- Knowledge Center
- About Us
At Abbott, the health and well-being of our customers and communities is our top priority.
For more than 130 years, we've put science and innovation to work - to create more possibilities for more people through the power of health. We adapt and respond quickly to changes in the world around us to deliver better solutions to help people live their best lives.
That commitment remains as we work to ensure continued supply, service and support to our valued customers and healthcare professionals during these times of global uncertainty.
abbott covid-19 product availability
patient monitoring
Monitoring in the Lab
With increased patient volume at healthcare facilities and the associated scarcity of
resources, evaluating disease severity can help optimize resource utilization by
ensuring that the appropriate level of treatment is provided.
HEMATOLOGY
The complete blood count (CBC), one of the most commonly performed tests
in the world, can be a fast and cost-effective way to support patient assessments.
procalcitonin (pct)
Recent studies suggest the value of PCT testing among COVID-19 patients, as some
patients may experience bacterial infections. This testing will help indicate who may
benefit from antibiotics as part of their treatment.
abbott covid-19 information
Additional covid-19 resources
As the situation concerning COVID-19 changes day to day, the following links may help you stay up-to-date on the latest developments.
join the conversation
Follow the Abbott Diagnostics LinkedIn Channel for the latest news from our company and within the in vitro diagnostics industry.
FOR THE LATEST ON
CORONAVIRUS,
GET ABBOTT EDGE DIRECTLY
TO YOUR INBOX
The Abbott SARS-C0V-2 IgG assay has not been FDA cleared or approved. It has been authorized by the FDA under EUA for use by authorized laboratories. This test has been authorized only for the detection of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
The Abbott RealTime SARS-CoV-2 assay and the Alinity m SARS-CoV-2 assay have not been FDA cleared or approved. These tests have been authorized by the FDA under an Emergency Use Authorization for use by authorized laboratories. These tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens, and are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
The ID NOW COVID-19 EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories and patient care settings. The test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 546(b)(1) of the Act, 21 U.S.C § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
The Abbott Point of Care i-STAT system does not offer any test cartridges for the diagnosis of COVID-19.
